Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLR1 | P15328 | 16/20 | 0.76 |
| ▸ | GART | P22102 | 15/20 | 0.76 |
| ▸ | SLC46A1 | Q96NT5 | 13/20 | 0.76 |
| ▸ | FOLR2 | P14207 | 13/20 | 0.76 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604391 | 0.86 | GART (1.00) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL1604397 | 0.86 | GART (1.00) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL18540805 | 0.85 | GART (0.77) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL1604405 | 0.79 | GART (0.73) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL10068239 | 0.79 | GART (0.90) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL1604410 | 0.79 | GART (0.78) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL1605446 | 0.78 | FOLR1 (1.00) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL1605455 | 0.78 | FOLR1 (1.00) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL18540790 | 0.76 | GART (0.91) | FOLR1GARTSLC46A1FOLR2SLC19A1 | |
| SCHEMBL18552695 | 0.76 | GART (0.69) | FOLR1GARTSLC46A1FOLR2SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994586-B2 | Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | CYP4F3, TYMS, DPYD | FOLR1 60/4885GART 11/4885SLC46A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.